On April 12, 2021 XNK Therapeutics AB ("XNK" or the "Company"), a Swedish clinical stage immunotherapy company treating cancer by developing novel NK cell-based therapies, reported the completion of a private placement of SEK 64 million (Press release, CellProtect Nordic Pharmaceuticals, APR 12, 2021, View Source [SID1234577885]). The purpose of the issue is primarily to finance the Company’s research and development efforts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"XNK has made significant progress with its technology platform and this new funding will be key to continue the clinical development of our leading investigational drug candidate," said Johan Liwing, CEO of XNK.